drugset / Trial / NCT04311645

Role of Activated Charcoal in Decreasing Blood Urea, Creatinine and Phosphorous

NCT04311645

Phase 2 Unknown 90 enrolled Assiut University
RandomizedParallel-groupOpen-labelTreatment

Summary

The study aims to explore the ability of Oral activated charcoal to adsorb uremic toxins limiting the progression of chronic kidney disease and delaying the need for hemodialysis in patients with CKD stages III and IV. To compare its effect with the effect of dry seeds as absorbents of uremic toxins

Timeline

Start
2020-08-01
Primary completion
2021-07-01
Completion
2021-08

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Activated Charcoal Other / unclassified 30 g Oral